IPR decision: Oct. 05, 2020
|AIA Review #||Filing Date||Institution Date||Petitioner||Patent||Respondent||Final Written Decision|
|IPR2016-01479||07/22/2016||02/15/2017||Par Pharmaceutical, Inc*.||9,006,224||Novartis AG||Challenged claims patentable|
*This proceeding as initially filed named Par Pharmaceutical, Inc. as the sole Petitioner. Argentum Pharmaceutical LLC was joined as a party to this proceeding via a Motion for Joinder in IPR2017-01063; West-Ward Pharmaceuticals International Limited was joined as a party via a Motion for Joinder in IPR2017-01078. Subsequently, Par and West-Ward separately requested termination of their participation in the proceeding pursuant to settlement. Argentum Pharmaceutical LLC is the sole remaining Petitioner.
US 9,006,224 (Novartis AG; Exp: 07/01/2028)
1. A method for treating pancreatic neuroendocrine tumors, comprising administering to a human subject in need thereof a therapeutically effective amount of 40-O-(2-hydroxyethyl)-rapamycin as a monotherapy and wherein the tumors are advanced tumors after failure of cytotoxic chemotherapy.